Year: 2021
Type: review
Source: The Lancet
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, glucose-lowering therapy, cardiovascular outcomes, heart failure, chronic kidney disease, cardiorenal disease, diabetic ketoacidosis, medullary thyroid carcinoma, pancreatitis, obesity, weight loss, end-stage renal disease, renal protection
Open Access status: bronze
OpenAlex ID: W3173421961
